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We retrospectively studied 38 Italian recently HIV-1-
infected subjects who seroconverted from 1994 to 1997
to investigate: (i) the prevalence of nucleoside reverse
transcriptase inhibitors (NRTI)-related mutations at
primary infection; (ii) the proportion of naturally occur-
ring mutations in reverse transcriptase (RT) and protease
regions of patients naive for non-nucleoside RT inhibitors
(NNRTIs) and protease inhibitors (PIs); (iii) the drug-
susceptibility to NRTIs and PIs in subjects with NRTI-
and/or PI-related mutations; and (iv) the outcome of
seroconverters treated with various NRTIs or NRTI/PI regi-
mens. Baseline HIV-1 plasma viraemia and absolute CD4
count at baseline could not be used to distinguish
patients with NRTI- and/or PI-related pre-existing muta-
tions from those with wild-type virus (P=0.693 and
P=0.542, respectively). The frequency of zidovudine-
related mutations was 21% in the study period. The
response to treatment was not significantly different in
subjects with or without genotypic zidovudine-related
mutations at primary infection (P=0.744 for HIV-1 RNA
and P=0.102 for CD4 cells). Some natural variation
(2.6%) was present within regions 98–108 and 179–190
of RT involved in NNRTI resistance. The high natural poly-
morphism in the protease region present in our patients
was similar to that reported by others. In our study some
PI-associated substitutions, thought to be compensatory
in protease enzymatic function, could confer interme-
diate to high PI-resistance. As discrepancies between
genotypic and phenotypic results may exist in recent
seroconverters, our data suggest that the role of trans-
mitted NRTI- and PI-resistant variants remain to be fully
elucidated in vivo.
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The risk of acquiring drug resistance at primary infec-
tion has become an emerging public health problem
following the widespread use of antiretroviral drugs in
developed countries. HIV-1-resistant strains may be
acquired both sexually [1–4] and vertically [5,6],
although the route of transmission seems to be irrele-
vant [7–10]. Recent reports have indicated a high
proportion of transmitted HIV-1-resistant variants in
therapy-naive individuals. In particular, strains that are
highly resistant to nucleoside RT inhibitors (NRTI) are
present in 1% of these subjects as determined by both
genotype and phenotype assays, while non-nucleoside
RT inhibitors (NNRTI) -resistant viruses may be found
in as many as 15–18% of naive patients [11–14].
Protease inhibitor (PI)-resistant variants have been
detected in 1–2% of recently infected subjects,
although discrepancies are reported between genotypic
and phenotypic results in the presence of a low number
of PI-related substitutions [11–14]. However, limited
studies have addressed the impact of the consequences
of transmission of HIV-1 resistant variants. Moreover,
few data are available to clarify the complex relation-
ship between genotypic changes occurring in pol gene
and phenotypic alteration of drug susceptibility of
HIV-1 isolates in recently seroconverted HIV-1-
infected individuals.
Our study investigated the prevalence of horizontal
transmission of NRTI-resistant strains several years
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after zidovudine, didanosine and zalcitabine introduc-
tion in clinical practice in Italy. Moreover, we
retrospectively investigated the effect of NRTI treat-
ment in subjects with transmitted resistant HIV-1
variants. In addition, we also studied the relationship
between genotypic and phenotypic results in our case
file.
The extensive use of PIs in seroconverters together
with previous observations of natural polymorphism in
the protease-encoding region among untreated
patients, and the occurrence of sexually transmitted PI-
related mutations of the protease region [15–18],
prompted us to determine the rate of pre-existing
mutations of protease region in recently infected
subjects. Moreover, although there is limited use of
NNRTIs in our country, we analysed the natural poly-
morphism of RT regions, encompassing both 98–108
and 179–190 residues, that have been reported to be
involved in resistance to NNRTIs [19].
Materials and Methods
Seroconverters
We enrolled a consecutive series of HIV-1 serocon-
verters from January 1994 to March 1997 at the
Institute of Infectious and Tropical Diseases of Milan.
HIV-1 infection was determined using ELISA anti-
bodies, and seroconversion was confirmed by Western
blot. Subjects with a time delay of >8 months between
the last negative and first positive antibody testing
were excluded from the study. Seroconverters were
followed up and treated according to the independent
decision of their clinicians. After June 1996 the sero-
converters were treated with HAART following the
Italian Guidelines for antiretroviral therapy.
Sample collection and preparation
Peripheral blood mononuclear cells (PBMCs) of
infected patients were obtained by gradient separation
from EDTA–blood samples. PBMCs were recovered,
washed three times in RPMI, centrifuged, pelleted and
cryopreserved in aliquots of 5–10×106 viable cells.
DNA extraction, amplification and sequencing
Cell-associated HIV-1 DNA from patients’ PBMCs was
extracted with the Elu-Quick isolation Kit (Schleicher
& Schuell). DNA was amplified by nested-PCR using
pol gene-specific primers to analyse all positions
known to confer resistance to zidovudine, didanosine,
zalcitabine, lamivudine, stavudine and PIs. Each reac-
tion mixture (100 µl) contained 10 mM Tris–HCl pH
8.3, 50 mM KCl, 1.5 mM MgCl2, 0.1 mM of each
dNTP, 2.5 U of AmpliTaq Gold DNA polymerase
(Perkin Elmer) and 50 pmol of each primer. Outer
primer pair was 1/2 for a region encompassing
protease and RT regions; inner primers for RT region
were 3/Seq I and Pia 3/4, as described elsewhere [20].
Inner primers for protease region were PRO-F
(nucleotide position 2197–2213, 5′TGTAAAAC-
GACGGCCAGTACAACAACTCCCTCTCA3′) and
PRO-R (nucleotide position 2628–2612,
5′CAGGAAACAGCTATGACCAATGGCCATTGTT-
TAAC3′). 1 µg of DNA was amplified during the first
PCR run. The reaction was initiated at 94°C for 9 min
(one hold); followed by 38 cycles at 94°C for 30 s,
45°C for 50 s and 72°C for 2 min and a final extension
cycle at 72°C for 10 min. The second amplification
was performed with 5 µl of the first amplification
product. The conditions employed were one hold at
94°C for 9 min, followed by two cycles at 95°C for 30
s, 45°C for 50 s and 72°C for 2 min, then 38 cycles at
94°C for 30 s, 55°C for 50 s, 72°C for 2 min, and a
final extension cycle at 72°C for 10 min.
Unincorporated primers and nucleotides were removed
with QIAQuick (Qiagen). PCR products were
sequenced directly using dye-labelled M13 primers and
ABI sequencing kit reagents (Applied Biosystem) in the
presence of 10% glycerol. A DNA automatic sequencer
377 (Applied Biosystems) was used. Sequence reaction
started with an initial cycle at 98°C for 1 min 30 s;
followed by 15 cycles at 98°C for 15 s, 55°C for 5 min
and 70°C for 2 min; and then 15 cycles at 98°C for 15
s and 70°C for 3 s.
Virus isolation and phenotype evaluation
HIV-1 isolates were obtained by cocultivation: 2×106
PBMCs taken from patients were cocultured with
2×106 PHA-stimulated (1 µg/ml) PBMCs taken from
healthy donors. Once a week, fresh 2-day PHA-pres-
timulated donor PBMCs were added to the cultures,
keeping a 1:1 final cell ratio, for 3 weeks in RPMI
medium supplemented with 20% fetal calf serum and
10 U/ml of recombinant IL-2 [21]. The culture super-
natants were sampled once a week and cryopreserved
at –80°C. HIV-1 p24 antigen was assayed in the culture
supernatants using a commercial ELISA (NEN, Life
Science Products). Virus phenotype was tested in the
MT-2 cell line as described [22].
Quantification of HIV-1 RNA and proviral DNA by a
reverse-transcription PCR assay and competitive PCR
HIV-1 copy numbers were determined using a quanti-
tative PCR assay (Amplicor HIV Monitor, Roche
Molecular Systems) which is based on a single
combined reverse transcription and amplification of a
conserved region of the gag gene, as well as of an
internal standard [23].
Lymphocyte subsets and HIV-1 p24 assay
Diagnostic monoclonal antibodies were employed to
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assess lymphocyte subsets by means of fluorocytom-
etry, using Coulter (Coulter Electronics) or Ortho
(Ortho Diagnostic Systems) cytometers.
Compounds
Zidovudine was obtained in powder form from
Wellcome Research Laboratories, UK. It was dissolved
in sterile PBS and stored at a concentration of 4 mM
in aliquots at –20°C until used. Indinavir and ritonavir
were obtained in powder form from Merck Research
Laboratories and Abbott Laboratories, respectively.
They were dissolved in sterile DMSO and stored at a
concentration of 1 mM in aliquots at –20°C until
used.
Viral titration
Viral titration was carried out in PBMCs, and the viral
titre, measured as the 50% tissue-culture infectious
dose (TCID50)/ml, was calculated by following the
method used by Reed & Muench [24].
Drug-susceptibility assay
RT and PI susceptibilities were determined using a
fixed amount of infectious virus (1000 TCID50/ml). The
isolated virus was used to infect 106 PHA-P-stimulated
PBMCs that were drug-free (control wells) or pre-
treated with four concentrations of zidovudine (0.01,
0.1, 1 and 10 µM) or four concentrations of indinavir
or ritonavir (0.005, 0.01, 0.05 and 0.1 µM) in dupli-
cate wells. After 7 days, the HIV-1 p24 antigen level
was measured in the cell-free supernatant of the
cultures. In all experiments, uninfected drug-treated
toxicity controls were maintained at the highest
concentrations of zidovudine, indinavir or ritonavir.
Cell proliferation and viability was assessed by the
Trypan blue exclusion method.
Computer-assisted data analysis
The analysis detected modified RT codons associated
with phenotypic resistance, and only the PI-related
positions were verified both genetically and pheno-
typically [19]. Data were assembled, manually
proofread and edited using the Factura and Sequence
Navigator software program (Perkin Elmer) to
discriminate the viral quasispecies. Sequences were
aligned with the consensus clade B sequence [25],
submitted to Genbank with assigned accession
numbers AF114267–AF114337.
Statistical analysis
The virological and molecular data were analysed
using Fisher’s exact test, or a generalization of it for
tables greater than 2×2 (Exact test for R×C tables), and
standard non-parametric methods (Kruskal–Wallis and
Mann–Whitney tests and Spearman rank correlation
coefficient). When patients’ results were below the
detection limit for the HIV-1 RNA assay in plasma,
comparisons of the medians in different groups were
conducted considering that HIV-1 plasma viraemia
was 200 copies/ml. These analyses were performed
using StatView version 4.5 (Abacus Concepts). For the
drug susceptibility assay, the 50% inhibitory concen-
tration (IC50) for each viral isolate was determined
using dose–effect analysis [26] with the Systat
computer software program for Macintosh, version
5.1. Comparison of mutation profiles for PIs among
naive and experienced subjects was performed using
Fisher’s exact test (Epi 6.0, CDC). Analysis of the level
of phenotypic drug resistance to the different
compounds was carried out using the Student’s t-test
(Systat).
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Table 1. Prevalence of transmitted zidovudine-associated mutations in 38 recently seroconverted individuals according to the
year of seroconversion and susceptibility of HIV-1 isolates to zidovudine in patients harbouring zidovudine-related mutations
Zidovudine-associated mutations Zidovudine IC50 (µM)*
Year n Patient RT positions n t0 t1†
1994 8 #3‡ 41L 1 0.089 0.0001
1995 14 #13‡ 70R 4 0.0025 –§
#15‡ 70R 2.5 10
#16‡¶ 70R 0.0001 –
#9‡ 70K/R; 219Q – –
1996 9 #25 70R 2 – –
#23 70K/R; 215 0.01 –
1997 7 #35 215Y 1 – –
*IC50 values represent the mean of two replicates. Values in bold are considered phenotypically resistant (>1 µM).
†6th month.
‡Patients retested for RT genotype at a further time point (6th month).
§Not determined.
¶Patient showed revertion of 70R substitution after 6 months.
Results
Virological characteristics of patients
In the study period we observed 38 recently infected
subjects with a documented seroconversion. Patients
had a median time lag between negative and positive
anti-HIV-1 antibody testing of 2.8 months (range,
1–8). Risk factors for HIV-1 infection were homo-
sexual contact in 17 cases, intravenous drug use in 10
and heterosexual contact in 11. Eight individuals did
not receive antiretroviral therapy during the study. All
but three patients who seroconverted after June 1996
were treated with HAART, including two NRTIs and
one PI. The remaining seroconverters were mainly
treated during the course of the infection with NRTI
combinations.
All the patients were studied for HIV-1 isolation and
phenotype evaluation. Eleven (28.9%) seroconverters
gave negative results for virus isolation at baseline. The
remainder showed NSI primary isolates with the
exception of two SI isolates. Median HIV-1 RNA
copies in plasma were 4.44 log10 (range, 3.11–6.17).
CD4 cell median count was 550 cells/mm3 (range,
300–1326). As expected, the levels of plasma viraemia
correlated with HIV-1 isolation (P=0.0079). HIV-1
RNA copies were inversely related to CD4 cell counts
with borderline statistical significance (ρ=–0.302,
P=0.0662). Although 13 seroconverters displayed very
high plasma viraemia (HIV-1 RNA >5 log10) at the time
of seroconversion, no correlation was observed
between the amount of HIV-1 cell-free virions and time
from seroconversion (ρ=–0.184; P=0.2623). In addi-
tion, no differences in HIV-1 RNA levels and CD4 cell
counts at baseline were detected between the eight
subjects with transmitted mutations (see below) and
the other patients. The median copies of HIV-1 RNA
were 4.75 log10, range 3.11–6.17 in the former group
and 4.42 log10, range 3.14–6.12 in the latter
(P=0.6937). The median CD4 cell counts were 444
cells/mm3 (range, 344–1326) and 557 cells/mm3 (range,
300–1193), respectively.
Genotypic and phenotypic resistance analysis of RT
region
Neither didanosine- and zalcitabine-related, or lamivu-
dine- and stavudine-related mutations were detected by
complete base-paired sequencing of RT region in the
case-file. The overall frequency of zidovudine-related
mutations was 21% in the 1994–1997 survey period.
The analysis performed revealed a prevalence of
12.5% in 1994, seroconverters (1/8) with a strain
bearing a M41L substitution and of 28.6% in 1995
seroconverters (4/14) with variants having four leading
mutations (of whose one was K70R plus K219Q). In
1996 the prevalence was 22.2% (2/9); in one subject
the predominant variant had a K70R change while the
other showed a major species with K70R plus T215Y
substitutions. The proportion of patients with zidovu-
dine-related mutations in 1997 was 14.3% (1/7) (Table
1). Five out of eight subjects with transmitted muta-
tions were genetically re-tested 6 months later. Only
one, harbouring a strain with 70R mutation, showed
the reversion of zidovudine mutant genotype as
detected by the predominant species of the viral popu-
lation.
In vitro susceptibility to zidovudine was assessed in
five patients bearing isolates with zidovudine-related
mutations (Table 2). At baseline, four out of five
isolates were zidovudine-sensitive (IC50 mean
value±SEM, 0.017±0.011 µM). The analysis of zidovu-
dine resistance for patient 15, who exhibited the K70R
mutation alone, revealed a persistently high phenotypic
profile both at baseline and after 6 months of observa-
tion. It is of note that this patient achieved partial
control of viral replication during both zidovudine
monotherapy and zidovudine/lamivudine association
therapy that was started at a later date. HIV-1 RNA
copies were 4.71 and 3.04 log10, while CD4 absolute
counts were 467 and 453 CD4 cells/mm3, at the indi-
cated time points. Patient 3, who had an IC50 of 0.089
µM at time 0, was re-evaluated 6 months later and
showed a maintenance of the IC50 in the sensitive range.
The frequency of natural polymorphism involving
98–108 and 179–190 RT coding portions was evalu-
ated in these seroconverters. One subject (2.6%)
displayed a K101E change.
Genotypic and phenotypic resistance analysis of
protease region
The frequency of spontaneous changes in HIV-1
protease coding region was analysed in 33 serocon-
verters. It should be noted that only five subjects
(15.2%) had no spontaneous mutations in comparison
to the reference strain [25]. Sixteen (48.5%), 10
(30.3%) and two (6%) individuals showed one, two,
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Table 2. In vitro susceptibility to indinavir and ritonavir in
seroconverted patients harbouring HIV-1 variants with or
without protease inhibitor mutations
IC50 (µM)*
Patient Protease mutations Indinavir Ritonavir
#31 L63P, A71T, V77I 0.01 0.01
#11 L63P 0.005 0.005
#36 L10I, L63P <0.01 0.0071
#38 L63P, I64V 0.033† 0.043†
#29 L10I, L63P 0.020† 0.056†
#23 No mutations <0.005 <0.005
*IC50 values represent the mean of two replicates.
†Phenotypically resistant (>0.01 µM).
and three amino acid substitutions at positions related
to PI resistance, respectively. The codon substitutions
more frequently involved were L63P/S/Q/T/C,
I64V/M, V77I, L10V/I, D60E, M36I/L and A71T/V
(found in 27, 7, 6, 5, 4, 4 and 3 cases, respectively).
To investigate the biological role of this high rate of
spontaneous mutation, we tested two PIs (indinavir
and ritonavir; saquinavir was not available from the
proprietary company) in five selected patients who
exhibited different PI-related multiple patterns of
mutations in their HIV-1 DNA sequences (Table 2).
Viral isolates were sensitive to indinavir in three out of
five subjects (IC50 mean value±SEM, 0.008±0.002 µM),
whereas they were moderately resistant in the other
two cases (IC50 higher than 0.01 µM). As for ritonavir,
three out of five isolates were sensitive (IC50 mean
value±SEM, 0.007±0.002 µM) and two were moder-
ately resistant or resistant (IC50 mean value±SEM,
0.076±0.012 µM), with statistically significant higher
values in the latter cases (Student’s t-test P=0.028).
However, the limited number of patients did not allow
us to correlate patterns of phenotypic resistance with
genotypic changes. The only patient who exhibited a
full phenotypic resistance to ritonavir (patient 38)
showed a genotypic profile with both mutations at
codons 63 and 64. Patient 29, who showed 63P and
10I substitutions, was partially resistant to PIs. To rule
out the possibility that these results could be an artifact
due to the differences between viral isolates and the
species amplified by PCR on proviral DNA, we
sequenced HIV-1 isolates that were used to perform the
susceptibility assays from patients 38 and 29. The
analysis of the sequences of both patients’ isolates
revealed a complete base pair identity with their
respective direct sequence counterparts.
Outcome of mutation-bearing seroconverters after
treatment
Thirty out of the 38 seroconverters received various
antiretroviral regimens that were established at sero-
conversion or later. Three seroconverters received
zidovudine alone in 1994 and 1995, 13 patients were
treated with two nucleoside analogues (10 subjects in
1994–1995 and three in 1996) while 11 patients were
subjected to highly active antiretroviral therapy
(HAART, two NRTIs and one PI) at seroconversion.
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Table 3. Virological and immunological outcome after 6 months of treatment in seroconverters with HIV-1 strains bearing
zidovudine- or protease inhibitor-related mutations and wild-type virus
HIV-1 RNA CD4 cell counts
(copies/ml) (counts/mm3) Time lag†
Patients t0* t1 t0 t1 Antiretroviral therapy (months)
(a) Patients treated with two NRTIs after variable time from conversion
#3‡ 4.71 2.81 509 386 ZDV/3TC 28
#13‡ 6.17 5.77 357 520 ZDV/ddI 2
#15§¶ 4.71 3.04 467 453 ZDV/3TC 14
#16‡ 4.07 2.70 475 621 ZDV/ddI 28
#25‡ 4.82 3.95 980 672 ZDV/ddI 1
#2 4.16 3.72 481 478 ZDV/ddI 15
#11 4.41 4.57 737 653 ZDV/ddI 26
#17 3.60 3.86 644 713 ZDV/ddI 4
#20 4.29 3.34 594 401 ZDV/3TC 7
#31 4.46 4.01 486 166 ZDV/ddI 7
(b) Seroconverters treated with HAART at seroconversion
#23‡ 5.09 3.46 344 382 ZDV/3TC/SQV 2
#35‡ 3.72 BLD 386 761 ZDV/3TC/IDV 3
#21 4.72 2.62 537 842 ZDV/3TC/SQV 3
#28 5.54 BLD 520 1054 ZDV/3TC/SQV 1
#29§ 5.22 3.62 612 650 ZDV/3TC/IDV 1
#32 4.46 BLD 415 707 ZDV/3TC/SQV 3
#33 4.46 BLD 509 1023 ZDV/3TC/IDV 2
#34 4.43 BLD 563 1045 ZDV/3TC/IDV 1
#36 5.13 3.95 733 827 ZDV/3TC/IDV 5
#37 6.06 BLD 746 986 ZDV/3TC/IDV 2
#38§ 6.12 BLD 517 922 ZDV/3TC/IDV 1
*t0, baseline for therapy; t1, 6 months.
†Time elapsed between HIV-1 seroconversion and treatment (months)
‡Subjects with zidovudine-related substitutions who resulted sensitive in in vitro drug assays.
§Patients who showed zidovudine or PI drug resistance.
¶Patient with K70R mutation in RT region, resulting in phenotypic resistance to zidovudine.
Abbreviations: ZDV, zidovodine; 3TC, lamivudine; ddI, didanosine; SQV, saquinavir; IDV, indinavir; BLD, below limit of detection of RT-PCR assay.
Table 3 shows the HIV-1 RNA and CD4 cell counts
at baseline and after 6 months of treatment in 10
subjects receiving similar combinations of NRTIs and
11 patients treated at seroconversion with HAART. All
therapeutic regimens included zidovudine. No statisti-
cally significant differences were present in subjects,
with or without transmitted zidovudine-related substi-
tutions who received two NRTIs as starting regimens
when virological and immunological profiles were
considered. The median counts of plasma HIV-1 RNA
and CD4 lymphocytes were 4.71 log10 (range,
4.07–6.17) or 4.29 log10 (range, 3.60–4.46), and 475
(range, 357–980) or 594 cells/mm3 (range, 481–737) at
baseline, respectively. After 6 months of therapy the
median values of plasma viraemia and CD4 cells were
3.04 log10 (range, 2.70–5.77) versus 3.86 log10 (range,
3.34–4.57), and 520 (range, 386–677) versus 478
cells/mm3 (range, 166–713), respectively (Table 3a).
Patients receiving three drugs showed a rapid decrease
in HIV-1 plasma viraemia, with values below the detec-
tion limit of the assay in seven out of 11 cases after 6
months. At the same time, an increase in the CD4 cell
count was observed (Table 3b). One subject with
zidovudine-related mutations (patient 23) showed a
modest reduction in plasma viraemia (1.63 log10) and a
10% increase in CD4 cells. However, this viral isolate
was sensitive to zidovudine and had neither PI-related
mutations, or evidence of phenotypic resistance to indi-
navir and ritonavir. The other subject (patient 35)
showing zidovudine-associated changes reached unde-
tectable levels of HIV-1 plasma viraemia with an
increase of 375 CD4 cells/mm3. Among seroconverters
treated with HAART at seroconversion, three addi-
tional subjects (patients 11, 29 and 36) did not achieve
undetectable levels of HIV-1 RNA. Their CD4 cell
counts increased by 57%, 6% and 13%, respectively. It
should be noted that patient 29 was found to be
phenotypically less susceptible to indinavir. In contrast,
patient 38 whose isolate was resistant to PIs, had a
marked reduction in plasma viraemia and a CD4 cell
count increase of 405 cells/mm3.
Discussion
Transmission of zidovudine-resistant HIV-1 variants
was first reported in 1993 [1]. Various studies have
demonstrated that 215F/Y RT mutations rose in the
USA from 1.4% in 1991 to 7.5% in 1992 and 10.4%
in 1993–1994 [7].
Early European data reported discrepancies that
might depend upon: (i) molecular methods used to
detect HIV-1 genetic mutations of pol gene; while
direct sequencing procedures distinguish both major
and minor HIV-1 species, the selective PCR, albeit very
sensitive, and the Line Probe Assay (LiPA), do not
provide information regarding the proportion of
different wild-type or mutated viral species [9,10]; (ii)
the viral compartments studied; cell-associated HIV-1
that was amplified in several surveys may not be equiv-
alent to cell-free virions that sustain HIV-1 replication
and spread of infection to target cells [2–4, 9,10]; (iii)
time of survey and the relative restricted use of NRTIs
in some countries in comparison to others [2–10, 27].
In our survey of newly infected individuals, neither
HIV-1 plasma viraemia or CD4 absolute count at base-
line distinguished between patients with NRTI- and/or
PI-related pre-existing mutations, and those with wild-
type virus. The response to treatment was not
influenced by the presence of zidovudine-related muta-
tions in the absence of phenotypically resistant isolates.
Our data suggest that about 20% of patients infected
after 1993 in the Milan area had zidovudine-resistance
related mutations. No difference was observed among
patients who belong to specific risk groups. Similar to
observations made in the USA, an increasing preva-
lence may be expected as a reflection of the widespread
use of this compound that requires a relatively long
time to develop a degree of resistance because of the
large number of mutations needed to overcome the
‘genetic barrier’. Notably, the leading zidovudine-
related K70R was the most represented mutation in
our group of patients. This mutation was observed in
six out of eight subjects with a predominance in 1995,
when regimens were frequently represented by zidovu-
dine alone or in association with another nucleoside
analogue. The absence of didanosine- and zalcitabine-
related mutations may be due to the limited use of
these drugs in comparison with zidovudine, as well as
to the low frequency of genetic changes conferred by
these compounds. The lack of a rapid lamivudine-
induced M184V substitution may depend upon both
the time of sampling and the fast reversion of this
mutation as detected in vitro [28] and in plasma
samples (unpublished data). Our data on zidovudine-
related resistance showed that four out of five
seroconverters with a transmitted genotypic variant
exhibited a fully sensitive phenotypic profile,
suggesting that isolates with this virological pattern
might respond to future antiretroviral treatment
including zidovudine. The clinical outcome of our
patients confirmed this hypothesis.
Although several studies aimed to define a correla-
tion between genotypic and phenotypic resistance and
virological failure [29–32], no final conclusions can be
drawn at present. Recent data by Wegner et al. [11]
indicated that the separate analysis of genotype and
phenotype in antiretroviral therapy-naive subjects may
provide conflicting results. This author found that
when the genotypic data suggest a ‘possible resistance’
(8% of the cases), the phenotypic results indicate the
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absence of PI resistance. One interpretation of this
finding may be that these subjects showing genotypic
mutations have a low number of changes in the
protease region. In addition, in these surveys the
phenotypic resistance to NRTIs was not fully predicted
by genotypic results. The overall frequency of NNRTI
polymorphisms detected in our case-file was 2.6%,
suggesting some spontaneous variation in RT regions
involved in NNRTI resistance. The effect of regimens
containing one NNRTI cannot be predicted on the
basis of present data.
Several studies indicate that patients subjected to
combination therapy including PIs showed a genotypic
profile with pre-existing mutations at the baseline
[15–17]. These substitutions involve positions that are
specifically selected by the use of PIs. Although a large
number of amino acid substitutions were evident in our
study, the naturally occurring amino acid changes were
entirely represented by secondary mutations [33] that
may play a role in conferring PI-resistance. Our results
confirm the occurrence of a large polymorphism in the
protease-coding region in recently infected individuals
and suggest that naturally occurring substitutions may
be involved in in vitro drug-resistance [34]. With
regards to patients investigated for phenotypic suscep-
tibility to PIs, three out of five patients with one to
three PI-related secondary mutations showed a sensi-
tive phenotype. Surprisingly, two of these patients
presented a moderate to high resistance phenotype that
could not be explained by the possible differences
among sequences of HIV-1 proviral DNA in compar-
ison to isolates obtained by co-cultivation.
Nevertheless, in one case we observed a partial
response to triple-drug therapy including a PI, while in
the other a marked control of viral replication was seen
after 6 months of therapy with HAART. In addition,
some of the pre-existing mutations correspond to
changes that are compensatory in protease enzymatic
function and their role in drug-naive subjects remains
to be established [35]. The administration of potent
combination regimens might have controlled the
growth of the viral strains less susceptible to PIs that
were detected before therapy. Moreover, our analysis
(direct sequencing) did not allow us to quantify the
phenotypically resistant variants. An additional
consideration, as suggested by Wainberg et al. [7], is
that resistant mutants may be disadvantaged in terms
of growth compared to wild-type virus in vivo in
recently infected patients not exposed to antiretrovi-
rals.
Even though anecdotal, our data suggest that
further information is needed in order to define the
correlation between the presence of secondary muta-
tions of protease pol region and its consequences on
phenotypic resistance and therapeutic benefits. We
must take into consideration that HIV-1 resistant vari-
ants may be preferentially transmitted compared to
other strains [7,18] and that little is known about the
selective fitness of these variants.
After considering that a certain proportion of trans-
mitted drug-associated mutations is emerging over
time, we believe that periodic surveys are required to
define the magnitude of transmitted antiretroviral
drug-resistance and to help clinicians in making thera-
peutic decisions in HIV-1 acute infection.
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